The role of carbapenems in the treatment of severe nosocomial respiratory tract infections, Expert Opinion on Pharmacotherapy, vol.43, issue.4, pp.561-75, 2008. ,
DOI : 10.1086/425368
Imipenem/Cilastatin, Drugs, vol.51, issue.1, pp.99-136, 1996. ,
DOI : 10.2165/00003495-199651010-00008
Les carbap??n??mes, R??animation, vol.18, issue.2, pp.199-208, 2009. ,
DOI : 10.1016/S1624-0693(09)75318-6
Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation, Diagnostic Microbiology and Infectious Disease, vol.68, issue.3, pp.251-259, 2010. ,
DOI : 10.1016/j.diagmicrobio.2010.06.012
Two decades of imipenem therapy, Journal of Antimicrobial Chemotherapy, vol.58, issue.5, pp.916-945, 2006. ,
DOI : 10.1093/jac/dkl354
Comparative Pharmacokinetics of the Carbapenems, Clinical Pharmacokinetics, vol.10, issue.2, pp.185-201, 2000. ,
DOI : 10.2165/00003088-200039030-00002
State???of???the???Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men, Clinical Infectious Diseases, vol.26, issue.1, pp.1-10, 1998. ,
DOI : 10.1086/516284
Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data, Journal of Antimicrobial Chemotherapy, vol.66, issue.2, pp.343-352, 2011. ,
DOI : 10.1093/jac/dkq348
Pharmacokinetic issues for antibiotics in the critically ill patient, Critical Care Medicine, vol.37, issue.3, pp.840-51, 2009. ,
DOI : 10.1097/CCM.0b013e3181961bff
Antimicrobial Therapy in Critically Ill Patients, Clinical Pharmacokinetics, vol.28, issue.12, pp.1009-1043, 2005. ,
DOI : 10.2165/00003088-200544100-00002
Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness, Intensive Care Medicine, vol.28, issue.12, pp.2145-56, 2004. ,
DOI : 10.1007/s00134-004-2428-9
Pharmacokinetic Changes in Critical Illness, Critical Care Clinics, vol.22, issue.2, pp.255-71, 2006. ,
DOI : 10.1016/j.ccc.2006.02.011
Imipenem Levels Are Not Predictable in the Critically Ill Patient, The Journal of Trauma: Injury, Infection, and Critical Care, vol.56, issue.1, pp.111-118, 2004. ,
DOI : 10.1097/01.TA.0000056164.26493.28
Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia, Pharmacotherapy, vol.16, issue.5, pp.924-955, 1996. ,
Tissue distribution of imipenem in critically ill patients, Clinical Pharmacology & Therapeutics, vol.71, issue.5, pp.325-358, 2002. ,
DOI : 10.1067/mcp.2002.122526
Pharmacokinetic Evaluation of Meropenem and Imipenem in Critically Ill Patients with Sepsis, Clinical Pharmacokinetics, vol.28, issue.3, pp.539-588, 2005. ,
DOI : 10.2165/00003088-200544050-00007
Population Pharmacokinetics and Pharmacodynamics of Continuous versus Short-Term Infusion of Imipenem-Cilastatin in Critically Ill Patients in a Randomized, Controlled Trial, Antimicrobial Agents and Chemotherapy, vol.51, issue.9, pp.3304-3314, 2007. ,
DOI : 10.1128/AAC.01318-06
Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion, Journal of Antimicrobial Chemotherapy, vol.63, issue.3, pp.560-563, 2009. ,
DOI : 10.1093/jac/dkn543
Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations, British Journal of Clinical Pharmacology, vol.45, issue.C, pp.61-71, 2011. ,
DOI : 10.1111/j.1365-2125.2010.03793.x
Optimization of meropenem dosage in the critically ill population based on renal function, Intensive Care Medicine, vol.51, issue.4, pp.632-640, 2011. ,
DOI : 10.1007/s00134-010-2105-0
Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients, Journal of Chromatography B: Biomedical Sciences and Applications, vol.692, issue.1, pp.127-159, 1997. ,
DOI : 10.1016/S0378-4347(96)00498-7
Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX Software, Journal of Pharmacokinetics and Pharmacodynamics, vol.32, issue.2, pp.229-278, 2007. ,
DOI : 10.1007/s10928-006-9043-z
URL : https://hal.archives-ouvertes.fr/inserm-00156907
Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model, Computational Statistics & Data Analysis, vol.51, issue.3, pp.1562-74, 2006. ,
DOI : 10.1016/j.csda.2006.05.007
URL : https://hal.archives-ouvertes.fr/inserm-00182360
Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, pp.1020-1058, 2005. ,
DOI : 10.1016/j.csda.2004.07.002
Ways to fit a PK model with some data below the quantification limit, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.5, pp.481-504, 2001. ,
DOI : 10.1023/A:1012299115260
A New Simplified Acute Physiology Score (SAPS II) Based on a European/North American Multicenter Study, JAMA: The Journal of the American Medical Association, vol.270, issue.24, pp.2957-63, 1993. ,
DOI : 10.1001/jama.1993.03510240069035
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure, Intensive Care Medicine, vol.21, issue.7, pp.707-717, 1996. ,
DOI : 10.1007/BF01709751
Altered pharmacokinetics of ceftazidime in critically ill patients, Antimicrob Agents Chemother, vol.43, issue.7, pp.1798-802, 1999. ,
Four hour creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients, Critical Care, vol.16, issue.3, p.107, 2012. ,
DOI : 10.2215/CJN.08531109
Replacement of 24-h creatinine clearance by 2-h creatinine clearance in intensive care unit patients: a??single-center study, Intensive Care Medicine, vol.75, issue.1, pp.1900-1906, 2007. ,
DOI : 10.1007/s00134-007-0745-5
How does late nephrological co-management impact chronic kidney disease? - An observational study, International Journal of Clinical Practice, vol.50, issue.4 Suppl. 3, pp.1784-92, 2010. ,
DOI : 10.1111/j.1742-1241.2010.02535.x
URL : https://hal.archives-ouvertes.fr/hal-00592307
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development???Part 2: Introduction to Pharmacokinetic Modeling Methods, CPT: Pharmacometrics & Systems Pharmacology, vol.14, issue.4, p.38, 2013. ,
DOI : 10.1177/0091270010376965
Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics, Journal of Pharmacokinetics and Pharmacodynamics, vol.27, issue.3, pp.15-33, 2014. ,
DOI : 10.1007/s10928-013-9343-z
URL : https://hal.archives-ouvertes.fr/inserm-00939284
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models, The AAPS Journal, vol.13, issue.2, pp.143-51, 2011. ,
DOI : 10.1208/s12248-011-9255-z
The lasso???a novel method for predictive covariate model building in nonlinear mixed effects models, Journal of Pharmacokinetics and Pharmacodynamics, vol.32, issue.2, 2007. ,
DOI : 10.1007/s10928-007-9057-1
Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data, International Journal of Antimicrobial Agents, vol.40, issue.5, pp.427-460, 2012. ,
DOI : 10.1016/j.ijantimicag.2012.06.011
Pharmacokinetic and Pharmacodynamic Considerations When Treating Patients with Sepsis and Septic Shock, Clinical Pharmacokinetics, vol.21, issue.14, pp.1135-51, 2002. ,
DOI : 10.2165/00003088-200241140-00002
Population Pharmacokinetics of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureus, Antimicrobial Agents and Chemotherapy, vol.50, issue.11, pp.3754-62, 2006. ,
DOI : 10.1128/AAC.00420-05